These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 9707265)

  • 1. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
    Parmley WW
    Am J Med; 1998 Jul; 105(1A):27S-31S. PubMed ID: 9707265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials.
    Young JB
    Int J Cardiol; 1994 Feb; 43(2):151-63. PubMed ID: 8181869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the treatment of heart failure.
    Giles TD
    Curr Opin Cardiol; 1994 Jul; 9 Suppl 1():S21-7. PubMed ID: 7827370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.
    Young JB
    Eur Heart J; 1993 Jul; 14 Suppl C():14-7. PubMed ID: 8365422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
    Young JB
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):89-102. PubMed ID: 7786840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure.
    Kiowski W; Sütsch G; Dössegger L
    J Cardiovasc Pharmacol; 1996; 27 Suppl 2():S19-24. PubMed ID: 8723395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of mild-to-moderate heart failure before the advent of beta blockers.
    Abraham WT; Wagoner LE
    Am J Med; 2001 May; 110 Suppl 7A():47S-62S. PubMed ID: 11334776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention with angiotensin-converting enzyme (ACE) inhibitors].
    Ertl G; Gaudron P; Neubauer S; Bauer B
    Z Kardiol; 1992; 81 Suppl 4():205-10. PubMed ID: 1290300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of angiotensin-converting enzyme inhibitors in congestive heart failure].
    Takeuchi K; Takeda T
    Nihon Rinsho; 1993 May; 51(5):1287-92. PubMed ID: 8331796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE-inhibitors in coronary artery disease?
    Vogt M; Motz W; Strauer BE
    Basic Res Cardiol; 1993; 88 Suppl 1():43-64. PubMed ID: 8357335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
    Doggrell SA
    Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.